Last reviewed · How we verify
JNS020QD
JNS020QD is a small molecule that targets the SGLT2 receptor.
JNS020QD is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | JNS020QD |
|---|---|
| Sponsor | Janssen Pharmaceutical K.K. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, JNS020QD reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study of JNS020QD in Patients With Chronic Pain (PHASE3)
- A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain (PHASE3)
- A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome (PHASE3)
- An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain (PHASE3)
- A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain (PHASE2, PHASE3)
- An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNS020QD CI brief — competitive landscape report
- JNS020QD updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI